These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
228 related articles for article (PubMed ID: 36672444)
1. Real-Life Study of the Benefit of Concomitant Radiotherapy with Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma (cSCC): A Retrospective Cohort Study. Bailly-Caillé B; Kottler D; Morello R; Lecornu M; Kao W; Meyer E; Dompmartin A; L'Orphelin JM Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672444 [TBL] [Abstract][Full Text] [Related]
2. Long-term survival after anti-PD-1 discontinuation in advanced cutaneous squamous cell carcinoma (cSCC): a proof of concept of benefit of concomitant cemiplimab and radiotherapy. Bailly-Caillé B; Levard R; Kottler D; Dompmartin A; L'Orphelin JM Cancer Immunol Immunother; 2024 May; 73(7):118. PubMed ID: 38713217 [TBL] [Abstract][Full Text] [Related]
3. Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma. Baggi A; Quaglino P; Rubatto M; Depenni R; Guida M; Ascierto PA; Trojaniello C; Queirolo P; Saponara M; Peris K; Spagnolo F; Bianchi L; De Galitiis F; Potenza MC; Proietti I; Marconcini R; Botticelli A; Barbieri V; Licitra L; Alfieri S; Ficorella C; Cortellini A; Fargnoli MC; Troiani T; Tondulli L; Bossi P Eur J Cancer; 2021 Nov; 157():250-258. PubMed ID: 34536948 [TBL] [Abstract][Full Text] [Related]
4. The Immunomodulatory Potential of Concurrent High-Dose Radiotherapy and Immune Checkpoint Inhibitor Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma: Initial Results. Lo Greco MC; Marano G; Milazzotto R; Liardo RLE; Finocchiaro I; La Rocca M; Basile A; Foti PV; Palmucci S; David E; Pergolizzi S; Spatola C J Pers Med; 2024 May; 14(6):. PubMed ID: 38929802 [TBL] [Abstract][Full Text] [Related]
5. A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6. Hughes BGM; Guminski A; Bowyer S; Migden MR; Schmults CD; Khushalani NI; Chang ALS; Grob JJ; Lewis KD; Ansstas G; Day F; Ladwa R; Stein BN; Muñoz Couselo E; Meier F; Hauschild A; Schadendorf D; Basset-Seguin N; Modi B; Dalac-Rat S; Dunn LA; Flatz L; Mortier L; Guégan S; Heinzerling LM; Mehnert JM; Trabelsi S; Soria-Rivas A; Stratigos AJ; Ulrich C; Wong DJ; Beylot-Barry M; Bossi P; Bugés Sánchez C; Chandra S; Robert C; Russell JS; Silk AW; Booth J; Yoo SY; Seebach F; Lowy I; Fury MG; Rischin D J Am Acad Dermatol; 2025 Jan; 92(1):68-77. PubMed ID: 39245360 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of Cemiplimab as Adjuvant or Neoadjuvant Therapy in the Treatment of Cutaneous Squamous Cell Carcinoma. Hiller A; Oxford M; Kulkarni P; Fornadley J; Lo A; Sivik J; Drabick J; Vakharia K Ann Plast Surg; 2024 Apr; 92(4S Suppl 2):S129-S131. PubMed ID: 38556660 [TBL] [Abstract][Full Text] [Related]
11. Cemiplimab in Ultra-Octogenarian Patients with Cutaneous Squamous Cell Carcinoma: The Real-Life Experience of a Tertiary Referral Center. Denaro N; Passoni E; Indini A; Nazzaro G; Beltramini GA; Benzecry V; Colombo G; Cauchi C; Solinas C; Scartozzi M; Marzano AV; Garrone O Vaccines (Basel); 2023 Sep; 11(9):. PubMed ID: 37766176 [TBL] [Abstract][Full Text] [Related]
12. Cemiplimab: A Review in Advanced Cutaneous Squamous Cell Carcinoma. Lee A; Duggan S; Deeks ED Drugs; 2020 Jun; 80(8):813-819. PubMed ID: 32306208 [TBL] [Abstract][Full Text] [Related]